Skip Navigation

Cardiovascular Research 2006 72(2):331-338; doi:10.1016/j.cardiores.2006.08.005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Doebis, C.
Right arrow Articles by Seifert, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doebis, C.
Right arrow Articles by Seifert, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators

Cornelia Doebisa,1, Sabine Schua, Juliane Ladhoffa, Annette Buscha, Florian Beyera, Jakob Reiserb, Roberto F. Nicosiac, Sabine Broesela, Hans-Dieter Volka and Martina Seiferta,*

aInstitute of Medical Immunology, Charité Universitätsmedizin Berlin, Monbijoustr. 2a, D-10117 Berlin, Germany
bLouisiana State University Health Sciences Center, Gene Therapy Program, 533 Bolivar Street CSRB 606 New Orleans, LA 70112, USA
cDivision of Pathology and Laboratory Medicine, Veterans Affairs Puget Sound Health Care System, 1660 Columbian Way, Seattle, WA 98108, USA

* Corresponding author. Tel.: +49 30 450524198; fax: +49 30 450524907. Email address: martina.seifert{at}charite.de

Objective: In vitro endothelialization has significantly improved the overall outcome of artificial prostheses in cardiovascular bypass surgery. A drawback of this tissue-engineering method remains the limited availability of suitable autologous endothelial cells (EC), especially in aged patients. Allogeneic EC with high proliferative capacity represent a potentially valuable alternative to a patient-specific vascular transplant. However, such cells carry the risk of being rejected due to Major Histocompatibility Complex (MHC) mismatches.

Methods: We investigated the effects of a very potent, intracellularly expressed antibody directed against MHC class I molecules, referred to as {alpha}-rat MHC I single chain variable fragment (sFv) intrabody. The intrabody was stably expressed in rat aortic EC (RAEC) following lentiviral vector-mediated gene transfer. The functional consequence of the MHC I down-regulation was tested in an allogeneic setting in two different in vitro assays.

Results: Stable expression of the {alpha}-rat MHC I sFv intrabody resulted in a highly efficient depletion of surface MHC I. Thereby those RAEC which displayed low MHC I levels over extended periods of time were protected against killing by allo-specific, cytotoxic T cells (CTL) and by allo-antibody/complement-mediated lysis.

Conclusions: These results demonstrate that intrabody-mediated down-regulation of MHC I reduces the immunogenicity of RAEC which may provide a suitable alternative supply for the lining of vascular prostheses.

KEYWORDS Endothelial cell; Gene therapy; Intrabody; Tissue engineering

1 Current address: Experimental Rheumatology, Charité Universitätsmedizin Berlin, c/o DRFZ, Charitéplatz 1, 10117 Berlin, Germany.

Time for primary review 28 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.